Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Financial Report: Teva | Contract Pharma

What are you searching for?

Sign in
Breaking News, Financial News

Financial Report: Teva

Branded revenues up 37%

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Teva

2Q Revenues: $5.0 billion (+19%)

2Q Earnings: $863 million (+50%)

YTD Revenues: $10.1 billion (+22%)

YTD Earnings: $1.7 billion (+27%)

Comments: Revenues in the U.S. in the quarter were $2.5 billion (representing 49% of total revenues), up 28%. Revenues in Europe were flat at $1.5 billion, or 30% of total revenues. Rest of the World (ROW) revenues were $1.1 billion (21% of total revenues), up 30%. Generic revenues were $2.6 billion, up 9%. Branded revenues were $1.9 billion, up 37%, primarily due to the inclusion of Cephalon sales (Treanda with $139 million, and Nuvigil with $91 million). Sales of Provigil dropped to $48 million due to generic competition. OTC revenues were $219 million, up 21%.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters